Vimian Group AB (publ) (STO:VIMIAN)

Market Cap	20.98B
Revenue (ttm)	4.24B
Net Income (ttm)	209.39M
Shares Out	523.89M
EPS (ttm)	0.40
PE Ratio	99.53
Forward PE	30.63
Dividend	n/a
Ex-Dividend Date	n/a

Volume	172,423
Average Volume	727,919
Open	41.00
Previous Close	40.42
Day's Range	39.34 - 41.00
52-Week Range	31.45 - 47.30
Beta	1.56
RSI	45.37
Earnings Date	Jul 18, 2025

About Vimian Group AB

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the I...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 1,200
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: VIMIAN

Financial Performance

In 2024, Vimian Group AB's revenue was 374.80 million, an increase of 12.99% compared to the previous year's 331.70 million. Earnings were 18.50 million, an increase of 88.78%.

Financial numbers in EUR